From PharmaTimes.com…..
Novo Nordisk’s glucagon-like peptide-1 (GLP-1) agonist semaglutide significantly cut body weight in a large-scale trial of adults who are overweight or obese.
Novo Nordisk’s ‘Semaglutide’ Shown To Cut Body Weight For The Overweight, Obese
Unprecedented results” for patients with obesity in 68-week trial
Loading…
